126 related articles for article (PubMed ID: 9713652)
1. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo.
Johnson BJ; Bekker LG; Rickman R; Brown S; Lesser M; Ress S; Willcox P; Steyn L; Kaplan G
Tuber Lung Dis; 1997; 78(3-4):195-203. PubMed ID: 9713652
[TBL] [Abstract][Full Text] [Related]
2. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis.
Johnson B; Bekker LG; Ress S; Kaplan G
Novartis Found Symp; 1998; 217():99-106; discussion 106-11. PubMed ID: 9949803
[TBL] [Abstract][Full Text] [Related]
3. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy.
Johnson BJ; Ress SR; Willcox P; Pati BP; Lorgat F; Stead P; Saha R; Lukey P; Laochumroonvorapong P; Corral L
Cytokines Mol Ther; 1995 Sep; 1(3):185-96. PubMed ID: 9384675
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: A systematic review and meta-analysis.
Zhang R; Xi X; Wang C; Pan Y; Ge C; Zhang L; Zhang S; Liu H
PLoS One; 2018; 13(7):e0201025. PubMed ID: 30024982
[TBL] [Abstract][Full Text] [Related]
5. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients.
Johnson BJ; Estrada I; Shen Z; Ress S; Willcox P; Colston MJ; Kaplan G
Infect Immun; 1998 Jun; 66(6):2426-33. PubMed ID: 9596698
[TBL] [Abstract][Full Text] [Related]
6. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
7. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
Koh WJ; Kwon OJ; Gwak H; Chung JW; Cho SN; Kim WS; Shim TS
J Antimicrob Chemother; 2009 Aug; 64(2):388-91. PubMed ID: 19468028
[TBL] [Abstract][Full Text] [Related]
8. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol.
Condos R; Rom WN; Schluger NW
Lancet; 1997 May; 349(9064):1513-5. PubMed ID: 9167461
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt.
Gadallah MA; Mokhtar A; Rady M; El-Moghazy E; Fawzy M; Kandil SK
J Formos Med Assoc; 2016 Nov; 115(11):997-1003. PubMed ID: 26696497
[TBL] [Abstract][Full Text] [Related]
10. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
12. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.
Johnson JL; Ssekasanvu E; Okwera A; Mayanja H; Hirsch CS; Nakibali JG; Jankus DD; Eisenach KD; Boom WH; Ellner JJ; Mugerwa RD;
Am J Respir Crit Care Med; 2003 Jul; 168(2):185-91. PubMed ID: 12702550
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, 1:1 randomized Phase III clinical trial of Immunoxel honey lozenges as an adjunct immunotherapy in 269 patients with pulmonary tuberculosis.
Batbold U; Butov DO; Kutsyna GA; Damdinpurev N; Grinishina EA; Mijiddorj O; Kovolev ME; Baasanjav K; Butova TS; Sandagdorj M; Batbold O; Tseveendorj A; Chunt E; Zaitzeva SI; Stepanenko HL; Makeeva NI; Mospan IV; Pylypchuk VS; Rowe JL; Nyasulu P; Jirathitikal V; Bain AI; Tarakanovskaya MG; Bourinbaiar AS
Immunotherapy; 2017 Jan; 9(1):13-24. PubMed ID: 27868466
[TBL] [Abstract][Full Text] [Related]
15. Effect of additional oral ofloxacin administration in the treatment of multidrug-resistant tuberculosis.
Sharma SK; Guleria R; Jain D; Chawla TC; Saha P; Mohan A; Jain NK
Indian J Chest Dis Allied Sci; 1996; 38(2):73-9. PubMed ID: 8822640
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis.
Drevlow BE; Lovis R; Haag MA; Sinacore JM; Jacobs C; Blosche C; Landay A; Moreland LW; Pope RM
Arthritis Rheum; 1996 Feb; 39(2):257-65. PubMed ID: 8849376
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis.
Bastos ML; Cosme LB; Fregona G; do Prado TN; Bertolde AI; Zandonade E; Sanchez MN; Dalcolmo MP; Kritski A; Trajman A; Maciel ELN
BMC Infect Dis; 2017 Nov; 17(1):718. PubMed ID: 29137626
[TBL] [Abstract][Full Text] [Related]
18. CD4(+)FoxP3(+) T regulatory cells in drug-susceptible and multidrug-resistant tuberculosis.
Lim HJ; Park JS; Cho YJ; Yoon HI; Park KU; Lee CT; Lee JH
Tuberculosis (Edinb); 2013 Sep; 93(5):523-8. PubMed ID: 23810735
[TBL] [Abstract][Full Text] [Related]
19. A new protocol for multiple inhalation of IFN-gamma successfully treats MDR-TB: a case study.
Grahmann PR; Braun RK
Int J Tuberc Lung Dis; 2008 Jun; 12(6):636-44. PubMed ID: 18492330
[TBL] [Abstract][Full Text] [Related]
20. Outcome of multi-drug resistant tuberculosis cases treated by individualized regimens at a tertiary level clinic.
Dhingra VK; Rajpal S; Mittal A; Hanif M
Indian J Tuberc; 2008 Jan; 55(1):15-21. PubMed ID: 18361306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
